Patent · US Active

Substituted indazoles as IRAK4 inhibitors

US11866405B2 · kind B2 · utility

0Cited by

0References

17Claims

0Family size

Assignee

ASTRAZENECA AB · SE

Inventors

Ina Terstiege · Gately Drive, SE
Stefan Schiesser · Linz, AT
Yafeng Xue · Timrå, SE
Hui-Fang Chang · Wilmington, US
Anna Berggren · Flyinge, SE

Key dates

Filing date	Dec 1, 2021
Grant date	Jan 9, 2024
Priority date	—
Expiry date	Dec 1, 2041

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61P37/08
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present application relates to chemical compounds of Formula (A): and pharmaceutically acceptable salts thereof, wherein X, R1, and R2 are as defined herein. The chemical compounds of Formula (A) inhibit IRAK4 and consequently have potential utility in medicine.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.